Dermal Regeneration Protocol for GLP-1/Pharmacologic Weight Loss Patients

Clinical Rationale

Abstract

The widespread adoption of GLP 1 receptor agonists (GLP 1 RAs) - including
semaglutide, tirzepatide, and liraglutide- has reshaped the landscape of pharmacologic
weight management. Alongside their metabolic benefits, recent
literature describes a distinct cutaneous phenotype characterised by volume
deflation and deterioration of skin quality. Evidence suggests that these changes
arise from a dual mechanism involving both structural fat pad depletion
and reduced fibroblast biosynthetic activity.
In this context, a new UK brand manufactured in Italy has developed a topical
cosmetic formulation designed to support skin physiology exposed to GLP 1
related metabolic stress. Its multi active composition—PDRN, dual molecular
weight hyaluronic acid, recombinant collagen, ectoin, and GHK Cu—targets
hydration, epidermal renewal, barrier protection, and extracellular matrix
(ECM) quality. All functions described refer exclusively to cosmetic support.